A clinical case of Inflammatory Bowel Disease (IBD) like colitis, induced by immune checkpoint inhibitors
https://doi.org/10.24884/1609-2201-2026-105-1-129-130
About the Authors
A. D. Kuzmina
Pavlov University
Russian Federation
Russian Federation
Anna D. Kuzmina, gastroenterologist
Saint Petersburg
E. I. Tselyakova
Pavlov University
Russian Federation
Russian Federation
Elena I. Tselyakova, Cand. of Sci. (Med.), gastroenterologist, Head of the Department of Therapy №2
Saint Petersburg
O. B. Shchukina
Pavlov University
Russian Federation
Russian Federation
Oksana B. Shchukina, Dr. of Sci. (Med.), Professor at Department of General Medical Practice (Family Medicine), supervisor of cabinet IBD
Saint Petersburg
References
1. Liu K., Wang Y. H., Luo N. et al. Treatment-related gastrointestinal adverse events of nivolumab plus ipilimumab in randomized clinical trials: a systematic review and meta-analysis. Future Oncol. 2023;19(27):1865‒1875. https://doi.org/10.2217/fon-2022-0615. PMID: 37753664.
2. Zoghbi M., Burk K. J., Haroun E. et al. Immune checkpoint inhibitor-induced diarrhea and colitis: an overview. Support Care Cancer. 2024;32(10):680. https://doi.org/10.1007/s00520-024-08889-2. PMID: 39311981; PMCID: PMC11420271.
3. Marthey L., Mateus C., Mussini C. et al. Cancer Immunotherapy with AntiCTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(4):395‒401. https://doi.org/10.1093/ecco-jcc/jjv227. PMID: 26783344; PMCID: PMC4946758.
Review
For citations:
Kuzmina A.D., Tselyakova E.I., Shchukina O.B. A clinical case of Inflammatory Bowel Disease (IBD) like colitis, induced by immune checkpoint inhibitors. New St. Petersburg Medical Records. 2026;(1):129-130. (In Russ.) https://doi.org/10.24884/1609-2201-2026-105-1-129-130
Views:
133
JATS XML
Email this article 